Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Pau Montesinos, Montserrat Arnan, Stephane De Botton, Maria Calbacho, Rebeca Rodriguez Veiga, Pierre Bories, Belén Ansoleaga, Thomas Hueso, Naval Daver, Lydia Wunderle, Andreas Harstrick, Kerstin Pietzko, Pallavi Hajela, Alexandra Vasile, Tania Witte, Elmarie Saenger, Christian Récher

Blood (2024) 144 (Supplement 1): 738.

https://doi.org/10.1182/blood-2024-194356

Published: 2024

Journal Articles

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Joseph Maakaron, Dipenkumar Modi, Matthew Mei, Tatyana Feldman, Gunjan L. Shah, Amitkumar N. Mehta, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Michael Emig, Lydia Wunderle, Andre Overesch, Alexandra Vasile, Jennifer Rubel, Thorsten Graef, Heather Raymon, Alison Moskowitz

Blood (2024) 144 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2024-193896

Published: 2024

Journal Articles

Genomic CDKN2A/2B deletions in adult Ph + ALL are adverse despite allogeneic stem cell transplantation

Blood (2018) 131 (13): 1464–1475.

https://doi.org/10.1182/blood-2017-07-796862

Published: 2018

Includes: Supplemental data

Journal Articles

Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study

Lydia Wunderle, MD, Susanne Badura, Fabian Lang, MD, Andrea Wolf, Eberhard Schleyer, MD, Hubert Serve, MD, Nicola Goekbuget, MD, Heike Pfeifer, MD, Gesine Bug, MD, PhD, Oliver G. Ottmann, MD

Blood (2013) 122 (21): 2675.

https://doi.org/10.1182/blood.V122.21.2675.2675

Published: 2013

Journal Articles

Treatment Outcome with Imatinib-Based Maintenance Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

Heike Pfeifer, MD, Barbara Wassmann, MD, Sylvia Wystub, MD, Lydia Wunderle, MD, Joerg Chromik, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Anja Binckebanck, Dieter Hoelzer, MD, Oliver Ottmann, MD

Blood (2007) 110 (11): 2817.

https://doi.org/10.1182/blood.V110.11.2817.2817

Published: 2007

Journal Articles

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Heike Pfeifer, Barbara Wassmann, Anna Pavlova, Lydia Wunderle, Johannes Oldenburg, Anja Binckebanck, Thoralf Lange, Andreas Hochhaus, Silvia Wystub, Patrick Brück, Dieter Hoelzer, Oliver G. Ottmann

Blood (2007) 110 (2): 727–734.

https://doi.org/10.1182/blood-2006-11-052373

Published: 2007

Journal Articles

Sustained Molecular Responses to Dasatanib (SPRYCEL®) in Patients with Philadelphia Chromosome-Positive (Ph(+)) Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase (LyBP) Chronic Myeloid Leukemia after Imatinib (IM) Failure: A Single-Center Experience.

Joerg Chromik, MD, Heike Pfeifer, MD, Lydia Wunderle, MD, Nadine Schoch, Barbara Wassmann, MD, Patrick Brueck, MD, Ashwin Gollerkeri, MD, Dieter Hoelzer, MD, PhD, Oliver G. Ottmann, MD

Blood (2006) 108 (11): 285.

https://doi.org/10.1182/blood.V108.11.285.285

Published: 2006

Journal Articles

Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).

Heike Pfeifer, MD, Barbara Wassmann, MD, Anna Pavlova, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Dieter Hoelzer, MD, PhD, Oliver Ottmann, MD

Blood (2006) 108 (11): 639.

https://doi.org/10.1182/blood.V108.11.639.639

Published: 2006

Journal Articles

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

Paul La Rosée, MD, Susanne Holm-Eriksen, Thomas Ernst, MD, Heiko König, MD, Philipp Erben, MD, Martin Müller, MD, Thomas Schenk, MD, Michael Emig, MD, Anja Binckebanck, MD, Lydia Wunderle, MD, Leila Alland, MD, Peter Schuld, MD, Rüdiger Hehlmann, MD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD

Blood (2005) 106 (11): 497.

https://doi.org/10.1182/blood.V106.11.497.497

Published: 2005

Journal Articles

A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns.

Heike Pfeifer, MD, Oliver G. Ottmann, MD, Nicola Goekbuget, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Aristoteles Giagounidis, MD, Michael Stelljes, MD, Andreas Hochhaus, MD, Harald Gschaidmeier, MD, Dieter Hoelzer, MD, Barbara Wassmann, MD

Blood (2005) 106 (11): 1824.

https://doi.org/10.1182/blood.V106.11.1824.1824

Published: 2005

Journal Articles

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

Heike Pfeifer, MD, Barbara Wassmann, MD, Anni Pavlova, MD, Martin Mueller, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Johannes Oldenburg, MD, Andreas Hochhaus, MD, Harald Gschaidmeier, MD, Dieter Hoelzer, MD, PhD, Oliver G. Ottmann, MD

Blood (2005) 106 (11): 147.

https://doi.org/10.1182/blood.V106.11.147.147

Published: 2005

NARROW

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Genomic CDKN2A/2B deletions in adult Ph + ALL are adverse despite allogeneic stem cell transplantation

Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study

Treatment Outcome with Imatinib-Based Maintenance Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Sustained Molecular Responses to Dasatanib (SPRYCEL®) in Patients with Philadelphia Chromosome-Positive (Ph(+)) Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase (LyBP) Chronic Myeloid Leukemia after Imatinib (IM) Failure: A Single-Center Experience.

Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns.

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only